Tim Hunt, CEO of the Alliance for Regenerative Medicine, contends that CGT companies are emerging stronger in 2026 from “hard lessons” learned after years of volatility.
As part of a previous pledge to invest $55 billion in the U.S., the drugmaker announced it will build two new manufacturing facilities in North Carolina and Pennsylvania.
The Japanese drugmaker is doubling down on its manufacturing investment in the antibody-drug conjugate market, where it remains the dominant global player.
Manufacturers face growing pressure to align drug design, production strategy, logistics, and workforce planning to ensure reliable, at-scale delivery.
Biomanufacturing scaling and supply chain resilience are top priorities for biopharma companies as they look to mitigate risks and capitalize on growth opportunities.
Revenues for publicly traded contract manufacturers will have doubled in five years when their fourth-quarter 2025 results are released, predicts new report from JLL.
In exchange for discounts to list prices on select medicines, the companies will receive relief from potential pharmaceutical tariffs over a three-year period.
Large pharmaceutical companies have promised to invest more than $370 billion over the next five years in the U.S., driven by Trump’s threat of pharma-specific tariffs.
The agency cited “significant violations” of current Good Manufacturing Practice regulations for finished pharmaceuticals at Novo Nordisk’s Bloomington facility.
The Swiss contract development and manufacturing organization is the only CDMO with available large-scale U.S. mammalian capacity, according to William Blair analysts.
Implementing autonomous manufacturing requires an expanded approach to continuous manufacturing that combines orchestration, seamless data flow, robotics, and intelligent simulation...
Contract research, development, and manufacturing organization Sai Life Sciences sees growing demand from Big Pharma clients diversifying away from China.
Following major investments in peptide and API capacities, CEO Thomas Loewald discusses supply chain localization, biotech funding trends, and scaling to meet demand.
The industry requires local resilience and flexibility in a complex global landscape, according to separate reports from consulting firms Deloitte and West Monroe.
The Huntsville active pharmaceutical ingredient site will produce small molecule synthetic and peptide medicines, including Lilly's oral GLP-1 orforglipron.
The company earlier this year purchased a Catalent drug product manufacturing facility in Somerset, New Jersey, securing its first footprint in the United States.
The deal is a win for Britain’s beleaguered pharma sector and comes after President Trump threatened to impose 100% tariffs on branded drugs imported to the U.S.
Report finds 40 states and Puerto Rico are offering sales and tax exemptions to lower costs for new biomanufacturing and research and development facilities.
The pharmaceutical company is investing in a greenfield project as it looks to resolve ongoing FDA compliance issues at three existing Indian facilities.
In a pharma trade deal between President Trump and British Prime Minister Starmer, the U.K.’s National Health Service will pay 25% more for innovative medicines.
With pledges of more than $370 billion over the next five years, the eastern U.S. remains the primary investment region, finds DPR Construction’s Q4 2025 report.
Agilent Technologies CEO Padraig McDonnell contends that Biovectra’s capabilities are well-positioned to take advantage of GLP-1s and their strong growth potential.
The company’s reduction in workforce comes as it continues to focus on implementing “innovative” manufacturing technologies to better produce novel drugs.
The company is adding to a biologics manufacturing site in Frederick and building a facility in Gaithersburg for the development and supply of drugs for clinical trials.